ReviewInternational journal of clinical and experimental pathology2026
Research progress on the regulation of miRNAs in diabetic kidney disease and osteoporosis.
Review in International journal of clinical and experimental pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) stands as one of the most prevalent chronic complications associated with diabetes mellitus. Conversely, osteoporosis (OP) represents another widespread metabolic bone disorder, one that exerts a substantial negative impact on the quality of life among diabetic populations. Together, these two conditions constitute significant threats to patient well-being. MicroRNAs (miRNAs), a class of endogenous non-coding RNA molecules typically around 22 nucleotides in length, exert pivotal regulatory functions across diverse physiological processes. These include critical cellular events such as proliferation, differentiation, apoptosis, and metabolic homeostasis. From the perspective of accumulating evidence, miRNAs have emerged as key regulators in the pathological mechanisms underlying both DKD and OP. Their influence on disease progression is mediated through the intricate modulation of key signaling pathways and target genes. The present review aims to synthesize the current understanding of the regulatory mechanisms, target gene profiles, and pertinent research advancements concerning miRNAs in diabetic nephropathy and osteoporosis. Furthermore, it attempts to consolidate the repertoire of miRNAs exhibiting potential therapeutic implications in both conditions. This work seeks to offer novel insights and actionable strategies for the early diagnosis, therapeutic intervention, and prognostic evaluation of patients suffering from DKD complicated with OP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.